Background: Chronic airway inflammatory diseases, such as chronic rhinosinusitis with nasal polyps and asthma, show increased nasal Staphylococcus aureus colonization. Staphylococcus aureus-derived serine protease-like protein (Spl) D and other closely related proteases secreted by S aureus have recently been identified as inducers of allergic asthma in human subjects and mice, but their mechanism of action is largely unknown. Objective: We investigated the role of recombinant SplD in driving T H 2-biased responses and IgE formation in a murine model of allergic asthma. Methods: Allergic asthma was induced in C57BL/6 J wild-type mice, Toll-like receptor (TLR) 4 knockout (Tlr4 2/2 ) mice, and recombination-activating gene (Rag2) knockout (Rag2 2/2 ) mice by means of repeated intratracheal applications of SplD. Inflammatory parameters in the airways were assessed by means of flow cytometry, ELISA, Luminex, and immunohistochemistry. Serum SplD-specific IgE levels were analyzed by using ELISA. Results: We observed that repeated intratracheal exposure to SplD led to IL-33 and eotaxin production, eosinophilia, bronchial hyperreactivity, and goblet cell hyperplasia in the airways. Blocking IL-33 activity with a soluble ST2 receptor significantly decreased the numbers of eosinophils, IL-13 1 type 2 innate lymphoid cells and IL-13 1 CD4 1 T cells and IL-5 and IL-13 production by lymph node cells but had no effect on IgE production. SplD-induced airway inflammation and IgE production were largely dependent on the presence of the functional adaptive immune system and independent of TLR4 signaling. Conclusion: The S aureus-derived protein SplD is a potent allergen of S aureus and induces a T H 2-biased inflammatory response in the airways in an IL-33-dependent but TRL4-independent manner. The soluble ST2 receptor could be an efficient strategy to interfere with SplD-induced T H 2 inflammation but does not prevent the allergic sensitization. (J Allergy Clin Immunol 2018;141:549-59.) 
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Key words: Allergy, asthma, Staphylococcus aureus, sensitization, serine protease Staphylococcus aureus is a versatile germ frequently found colonizing patients with T H 2-biased diseases, such as atopic dermatitis and chronic rhinosinusitis with nasal polyps. [1] [2] [3] [4] [5] It actively manipulates the host immune response by releasing proteins that facilitate bacterial invasion and colonization. 6, 7 These secreted proteins allow the bacterium to activate virulence and metabolic pathways required for bacterial survival and might exert immunosuppressive action on the mucosal environment. 8, 9 Based on in silico analyses of the S aureus pangenome, it is estimated that the repertoire of secreted proteins comprises more than 1350 proteins, including enterotoxins, toxic shock syndrome toxin 1, and other virulence factors, and for many of these, the function is unknown. 10, 11 It is important to understand the interplay between the immune proteome of S aureus and the immune response of the host and to elucidate its role in the initiation and persistence of chronic airway diseases. Asthmatic patients have increased specific IgE reactivity to various secreted S aureus proteins, 12 and several endotypes of chronic rhinosinusitis were proposed based on the presence of S aureus-specific IgE. 5, 13 Recently, we have observed increased levels of Staphylococcus aureus serine protease-like protein (Spl)-specific IgE in sera of asthmatic patients, indicating the clinical relevance of these proteases.
14 Spls are a group of 6 S aureus proteases (SplA-SplF) that belong to the small subfamily S1B (encompassing staphylococcal V8 protease, epidermolytic toxins, and Spl proteases). Eightyfour percent of S aureus strains contain at least 1 Spl protease-encoding gene. 15 Moreover, we could demonstrate that repeated exposure to pure SplD without the addition of any adjuvant results in a T H 2 response and SplD-specific IgE production in mice. 14 However, the exact mechanisms underlying this SplD-induced T H 2 bias are not yet unraveled and are the focus of the current study.
Allergens, such as house dust mite (HDM), cockroach, or Alternaria alternata, were shown to play an important role in allergy development in part through activation of cell surface protease-activated receptors (PARs) 16 in the airways, inducing cytokines and cleave intercellular epithelial tight junctions 17 and thereby amplifying the response to allergens. They can also cleave CXCR1 on the surfaces of neutrophils 18 and CD23 and CD25 receptors on immune cells, 19 thereby reinforcing allergy progression.
A key mediator of the type 2 inflammation of the airways is the cytokine IL-33. IL-33 binds to a heterodimeric cell-surface receptor consisting of IL-1 receptor accessory protein and ST2 on immune cells, such as T H 2 cells, type 2 innate lymphoid cells (ILC2s), invariant natural killer T cells, natural killer cells, basophils, eosinophils, mast cells, and dendritic cells (DCs), eventually activating intracellular signaling pathways and supporting allergic airway inflammation. [20] [21] [22] Among the 4 known isoforms of ST2, 2 are highly relevant for the regulation of allergic airway 23 It has been shown that sST2 antagonizes ST2, suppressing the IL-33-mediated activation of the nuclear factor kB (NF-kB) pathway, as well as downstream effects, such as T H 2 cytokine production, thereby attenuating allergic asthma symptoms in mice. 24, 25 In this respect sST2 could be a promising therapeutic option for asthma.
In the current work we focused on the molecular mechanisms by which SplD drives allergic asthma in mice. We demonstrated that SplD-induced type 2 cytokine production and eosinophilia in the airways are largely IL-33 dependent, whereas production of SplD-specific IgE and goblet cell metaplasia occur independently of this pathway. The abovementioned effects are mediated by the adaptive immune system.
METHODS

Mice and sensitization protocol
Animals were maintained in a 12-hour/12-hour light/dark cycle and had access to water and food ad libitum. Animal experiments were approved by the local ethics committee of Ghent University. Female C57BL/6 J wild-type mice (Janvier, Heverlee, Belgium), Toll-like receptor (TLR) 4 knockout (Tlr4 2/2 ) mice and recombination-activating gene (Rag2) knockout (Rag2 2/2 ) mice (both kindly provided by VIB-IRC, Ghent, Belgium) were treated after achievement of light anesthesia with isoflurane/air (Ecuphar, Oostkamp, Belgium) 6 times every second day by means of intratracheal applications with either 45 mg of SplD, 45 mg of SplF, or 100 mg of ovalbumin (OVA; Worthington Biochemical, Lakewood, NJ) in 50 mL of PBS (Gibco, Thermo Fisher Scientific, Erembodegem-Aalst, Belgium) and 1 additional intratracheal application of 50 mL of PBS after each treatment or 50 mL of PBS alone. In some experiments a combination of 45 mg of SplD and 100 mg of OVA was administered 6 times every second day by means of intratracheal application. sST2 was applied intratracheally at a dose of 25 mg/50 mL per mouse after each SplD application instead of the second PBS application. Forty-eight hours after the last intratracheal application, mice were killed with an intraperitoneal injection of 100 mL of Nembutal (Ceva Sant e Animale, Libourne, France), and the lungs, serum, bronchoalveolar lavage fluid (BALF) and local draining lymph nodes were collected in each experiment.
Luminex analysis
Concentrations of murine IL-5, IL-13, IL-33, and eotaxin in lung homogenates and lymph node cell supernatants were analyzed by using Luminex Performance assays (R&D Systems, Oxon, United Kingdom). IL-25 
Bronchial hyperreactivity test
Bronchial hyperreactivity in response to increasing doses of carbachol (0, 20, 40, 80, 160, 320, and 640 mg/kg) was measured 48 hours after the last intratracheal application by using the forced oscillation technique (flexiVent System, SCIREQ, Montreal, Quebec, Canada). Neuromuscular blockade was induced by injecting 1 mg/kg pancuronium bromide intravenously. A ''snapshot perturbation'' maneuver was imposed to measure the resistance of the whole respiratory system (airways, lung, and chest wall).
Flow cytometry
The list of antibodies used in the study and the gating strategy are provided in the Methods section in this article's Online repository at www.jacionline.org.
Statistics
Statistical analysis was performed by using GraphPad Prism version 6 software (GraphPad Software, La Jolla, Calif) and the unpaired nonparametric Mann-Whitney test.
A more detailed description of the materials and methods used in this study can be found in the Methods section in this article's Online Repository.
RESULTS
SplD induces key features of asthma and increased expression of IL-33 in mice
We established a sensitization protocol using C57BL/6 J wild-type mice that received 6 intratracheal applications of 45 mg of SplD. Mice treated with PBS or the inert antigen OVA served as negative control groups. With this model, we previously demonstrated that SplD could attract eosinophils and T cells to the airways, increase T H 2 cytokine production in local draining lymph nodes, and induce formation of SplD-specific IgE.
14 To study the mechanisms of the type 2-biased asthmatic response to SplD, we investigated IL-33 expression in this mouse model. IL-33 is a crucial cytokine in the setting of type 2 allergic inflammation. 20, 26 After SplD exposure, mice expressed higher levels of IL-33 in lung homogenates than control mice. Full-length IL-33 and, even more distinctly, the cleaved form of IL-33 were (Fig 2, B) and flow cytometric analysis of eosinophils (CD11c Fig 2, D) , and (Fig 2, F) and IL-5-producing (Fig   2, G) and IL-13-producing (Fig 2, H) ILC2s in BALF. I-K, Eosinophils (Fig 2, I ), neutrophils (Fig 2, J) , and CD4 1 T cells (Fig 2, K) in lungs analyzed by using flow cytometry. L and M, IL-33 (Fig 2, L) and eotaxin (Fig 2, M ) measurement of lung homogenates by using Luminex. Mean 6 SEM values are presented. N 5 7-13. *P < .05, **P < .01, ***P < .001, and ****P < .0001, Mann-Whitney U test. n.s., Not significant.
increased in SplD-treated mice (Fig 1, A) . ) in all treatment groups (Fig 1, B) , whereas more IL-33
1 cells were present in SplD-treated mice. Because IL-33 was shown to be an alarmin that can be passively released during necrosis, 27 we have analyzed cell death in the lungs of SplD-treated mice. Western blotting for phosphorylated mixed lineage kinase domain-like protein (pMLKL), which becomes phosphorylated on cell necrosis, 28 was not detectable in the experimental animals, irrespective of treatment (see Fig E1, A, in this article's Online repository at www.jacionline.org). In addition, no terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive cells in the lung sections were detected either (see Fig E1, B) , supporting that neither apoptotic nor necrotic cell death has a prominent role in the SplD-induced generation of IL-33 in murine airways. Isolated primary murine AECIIs responded to SplD with an increased expression of fulllength IL-33, which peaked after 1 hour (Fig 1, C) . We did not find an increase in TSLP, IL-25, and GM-CSF levels in the lungs of mice treated with SplD compared with those in control mice (data not shown).
The IL-33/ST2 axis modulates type 2 inflammatory responses in a murine model of SplD-induced asthma SplD-sensitized mice were treated with intratracheal applications of the recombinant soluble IL-33 receptor sST2 after each SplD treatment to block IL-33 signaling to investigate the role of IL-33 in SplD-induced asthma (Fig 2, A) . sST2 treatment significantly reduced total cell numbers and eosinophil counts in BALF (Fig 2, B and C) . The low number of neutrophils attracted to the BALF on SplD exposure was further reduced in sST2-treated mice (Fig 2, D) . SplD treatment induced an infiltration of CD4 1 T cells into the BALF (Fig 2, E) . Furthermore, activation of T H 2 cells and ILC2s was evident by the increased numbers of IL-13
1
CD4
1 T cells and ILC2s and IL-5-producing ILC2s in the BALF, which were significantly reduced after sST2 treatment (Fig 2, F 
-H).
Eosinophil numbers were reduced in tendency in the lungs of SplD-exposed mice treated with sST2 (Fig 2, I ). No neutrophil infiltration into the lungs of SplD-exposed mice was observed (Fig 2, J) . sST2 caused a significant reduction in the number of CD4 1 T cells in the lungs (Fig 2, K) . IL-33 and eotaxin levels (Fig 3, A) , flow cytometric analysis of DCs in lymph nodes (Fig 3, B) , and cytokine release by lymph node cells (Fig 3, C and D) after stimulation for 5 days with anti-CD3 and anti-CD28 antibodies or medium (RPMI, controls). E and F, SplD-specific IgE (Fig 3, E) and OVA-specific serum IgE (Fig 3, F) concentrations of mice treated with either PBS, OVA, SplD, or a combination of SplD and sST2 or SplD and OVA were measured by using ELISA. G, Airway resistance in response to increased doses of carbachol administered 48 hours after the last intratracheal challenge of PBS, OVA, SplD, or SplD and sST2 was measured by using a forced oscillation technique. N 5 7-13. Results are presented as means 6 SEMs. *P < .05, **P < .01, ***P < .001, and ****P < .0001, Mann-Whitney U test. n.s., Not significant.
exhibited a tendency to decrease when sST2 was given in addition to SplD (Fig 2, L and M).
In the lung draining lymph nodes, the total cell count was not significantly altered by sST2 treatment (Fig 3, A) ; however, the increase in MHC class II 1
CD11c
1 DCs that was observed after SplD treatment was significantly dampened when sST2 was given in addition (Fig 3, B) . Local draining lymph node cells from mice receiving different experimental treatments were restimulated with aCD3 and aCD28 antibodies for 5 days to analyze the effect of the IL-33 signaling pathway on T-cell polarization. SplD-treated mice had a significantly higher T H 2 cytokine production (ie, IL-5 and IL-13 levels in the lymph node cell supernatants) compared with the PBS-treated groups, corroborating our earlier findings in the same model, 14 although T H 1 and T H 17 differentiation were not affected (data not shown). Remarkably, sST2 treatment resulted in a strong reduction of IL-5 and IL-13 levels in lymph node cell supernatants of SplD-treated mice (Fig  3, C and D) , supporting the notion of an important role of IL-33 in SplD-induced T-cell activation. Although the inflammatory cell responses were dampened by sST2 treatment, serum levels of SplD-specific IgE were not significantly reduced by sST2 (Fig 3, E) . Moreover, SplD exposure induced bronchial hyperreactivity, which was partially but not significantly decreased by sST2 treatment (Fig 3, G) .
To further characterize our SplD sensitization model, we investigated lung histology. SplD-treated mice showed marked perivascular and peribronchial infiltration of CD45 1 leukocytes, which was largely prevented by sST2 (Fig 4, A) . The key features of asthma, such as goblet cell hyperplasia in the airways (Fig 4, B) and thickening of the peribronchial airway smooth muscles, were present in the SplD-treated mice and indicate incipient airway remodeling (Fig 4, C) . These were unchanged after addition of sST2.
In summary, our results underline the crucial role of IL-33 in SplD-induced type 2 inflammation, whereas airway remodeling features were less affected by intratracheal administration of sST2.
SplD acts as an adjuvant when coadministered with an inert allergen
As we have shown, SplD administration in the absence of adjuvants results in production of SplD-specific serum IgE in mice (Fig 3, E) .
14 In contrast, OVA alone did not induce an OVAspecific IgE response under similar conditions because it is considered an inert antigen. Remarkably, intratracheal coadministration of SplD breaks the tolerance to OVA, as shown by significantly higher levels of OVA-specific serum IgE in the mice (Fig 3, F) .
SplD induces attraction of PAR2
1 cells to the lungs PAR2 is an important recognition receptor for protease allergens, such as HDM or A alternata, and its activation enhances a T H 2 response in the lungs. 29, 30 After SplD treatment, numbers of PAR2 1 cells were significantly increased in the lungs, which could be efficiently counteracted by sST2 (Fig 5, A) . This indicates that the increased PAR2 expression in the lungs is a consequence of the SplD-induced attraction of inflammatory cells rather than a direct activation of PAR2. Both an in vitro assay with NF-kB-dependent PAR2 reporter HEK-293 cells (Fig 5, B) and green fluorescent protein (GFP)-tagged PAR2-expressing HeLa cells (Fig 5, C) showed activation with the PAR2 activating peptide SLIGKV-NH 2 and trypsin by luciferase activity or internalization of PAR2 by endosome formation but not with SplD.
SplD does not activate TLR2 in vitro
TLR2 is a receptor that detects bacterial cell wall compartments, such as peptidoglycan, and is thus involved in recognizing S aureus. 31 SplD did not activate TLR2 reporter cells (HEK-Blue hTLR2) in vitro at any tested concentration, excluding a direct interaction of SplD with TLR2 (see Fig E2, A, in this article's Online repository at www.jacionline.org).
SplD induces asthma features independent from TLR4
Inhalation of allergens with proteolytic capacities, such as HDM, leads to asthma through initiation of the TLR4 signaling pathway. 32 However, the numbers of eosinophils, neutrophils, or T cells in BALF and lungs were comparable between wild-type and Tlr4 2/2 mice when treated with SplD (see Fig E2, B-F) . In addition, TLR4 deficiency did not affect levels of SplD-induced IL-33 production (see Fig E2, G) and SplD-specific IgE (see Fig E2, H) production. This indicates that, in contrast to HDM, SplD-induced asthma is TLR4 independent.
The adaptive immune system is essential for SplDinduced asthma
To study the contribution of the adaptive immune system to SplD-induced allergic airway inflammation, we treated Rag2 2/2 mice, which lack mature T and B cells but not ILC2s, 33 with SplD or PBS. SplD-induced eosinophilia in the BALF was completely abolished in Rag2 2/2 mice (Fig 6, A) , and neutrophil counts were significantly increased in BALF of SplD-treated Rag2 2/2 mice compared with those in control mice (Fig 6, B) . IL-33 levels in the lungs of SplD-treated Rag2 2/2 mice were comparable with those of the control mice, indicating that IL-33 acts upstream of the adaptive immune system (Fig 6, C) . No production of SplDspecific IgE could be measured in Rag2 2/2 mice (Fig 6, D) .
Histologic analysis of the lungs showed that Rag2 2/2 mice do not respond to SplD because they lack inflammatory cell infiltration, airway remodeling, or bronchial hyperreactivity (Fig 6, E-I ), which were observed in the wild-type mice. The absence of a (Fig 6, A) and neutrophils (Fig 6, B) in BALF, IL-33 measurement of lung homogenates by using Luminex (Fig 6, C) , and SplD-specific IgE measurement in serum (Fig 6, D) by means of ELISA of PBS-or SplD-treated Rag2 2/2 mice in comparison with wild-type mice. E-H, Anti-CD45 staining and quantification (Fig 6, E) , periodic acid-Schiff (PAS) staining and goblet cell count (Fig 6, F) , anti-smooth muscle actin (SMA) with measurement of the peribronchial airway smooth muscle thickness (Fig 6, G) , and anti-PAR2 staining and quantification on lung sections (Fig 6, H) . I, Airway resistance in response to increased doses of carbachol administered 48 hours after the last intratracheal challenge of PBS-or SplD-treated Rag2 2/2 mice was determined by using the forced oscillation technique. Scale bar 5 200 mm. N 5 5-8. Means 6 SEMs are presented. *P < .05, ***P < .001, and ****P < .0001, MannWhitney U test. n.s., Not significant.
functional immune system in Rag2 2/2 mice does not allow analysis of the humoral immune response.
The serine protease-like protein SplF induces an inflammatory response similar to that of SplD SplF is also encoded in the Spl-Operon and shares high sequence similarity with SplD. We tested the response to SplF in vivo by using the same protocol as with SplD. In the BALF of SplF-treated mice, total cell counts (see Fig E3, A, in this article's Online repository at www.jacionline.org), as well as numbers of eosinophils (see Fig E3, B) , neutrophils (see Fig E3,  C) , and CD4
1 T cells (see Fig E3, D) , were significantly higher than in the PBS-treated control mice. Eosinophil counts are also increased in the lungs (see Fig E3, E) , whereas neutrophil counts remained low (see Fig E3, F) . A trend toward increased expression of IL-33 and eotaxin was also observed (see Fig E3, G and H). After 6 applications of SplF, SplF-specific IgE was formed (see Fig E3, I ). Representative images of CD45 1 leukocytes attracted to the lungs, goblet cells, peribronchial smooth muscles, and PAR2
1 cells show results comparable to those in SplDtreated mice (see Fig E3, J) .
DISCUSSION
In this study we focus on the mechanisms of the T H 2-biased immune response induced by SplD. Our study reveals that sensitization with SplD causes allergic airway inflammation in mice accompanied by release of the innate cytokine IL-33, increased airway hyperreactivity, greater mucus production, and activation of the adaptive immune system with predominant release of T H 2 cytokines. Allergen recognition in the airways is characterized by release of IL-1a, IL-25, IL-33, TSLP, GM-CSF, and endogenous danger signals that activate the DC network and other innate immune cells, such as basophils and ILC2s. 34 In contrast to earlier observations in HDM sensitization models, we did not find an increase in TSLP, IL-25, and GM-CSF levels in the lungs of mice treated with SplD.
It became evident that IL-33 and its receptor ST2 are crucial in regulation of allergic inflammation. 24, 35 IL-33 is expressed by airway smooth muscle cells and endothelial and epithelial cells, and it can also be produced by macrophages on activation in human subjects. 36 In murine lungs IL-33 is mostly localized in AECIIs. 37 IL-33 can be released as an alarmin from dying cells 27 or on allergic sensitization. 21, [38] [39] [40] In this study we showed that IL-33 expression levels are increased in SplD-treated mice in comparison with the control mice. By stimulating isolated primary AECIIs with SplD in vitro, we demonstrated a fast and direct effect of SplD on IL-33 production that was independent of the presence of inflammatory immune cells. Importantly, IL-33 upregulation was not accompanied by cell death, as demonstrated by TUNEL staining of lung sections and Western blotting for pMLKL, suggesting that IL-33 is not passively released by dying cells but actively secreted by the airway epithelium. Bacterial and fungal cell wall components were shown to induce IL-33 production through TLR2 activation 41 ; however, SplD did not directly activate TLR2 in vitro. Moreover, we demonstrated that the facilitating effects of SplD on allergy parameters, such as eosinophilia, T H 2 cytokine production, and SplD-specific IgE levels, appeared to be independent of TLR4. This observation is in sharp contrast to the mode of action described for HDM, where the presence of TLR4 on the structural lung cells is required for the development of allergic asthma. 32 This suggests the possibility that other receptors might be involved, such as PAR2, which is triggered, for example, by A alternata, to induce an asthmatic response independent of TLR4. 42 PAR2 activation in the lungs was shown to trigger and enhance a T H 2-biased inflammatory response to an inert protein antigen in mice. 43 We observed an increase in PAR2 1 cell counts in lung sections of SplD-treated mice. The higher amount of PAR2 in SplD-treated mice can be explained by PAR2 expression on immune cells, such as CD4 1 T cells 44 or macrophages infiltrating SplD-treated lungs, and by the effects of endogenous proteases that are released, such as by mast cells in response to the SplD-induced inflammation. 45 We have demonstrated that no direct protease-dependent activation of PAR2 by SplD occurs.
We have observed an increased production of IL-5 and IL-13 in lymph nodes of SplD-treated mice. Because IL-13 promotes continuous IL-33 production, 46 positive feedback loops could drive allergic airway inflammation in our model. The presence of both uncleaved and cleaved forms of IL-33 in the lungs of mice treated with SplD could be very important because the mature short form of IL-33 has a 30-fold increased capacity to activate ILC2s ex vivo through ST2. 47 We have ruled out the possibility that SplD could directly cleave IL-33 in vitro because no fragments were generated after coincubation with full-length IL-33 for up to 24 hours (data not shown). Alternatively, IL-33 activity can be regulated by endogenous proteases released during inflammation. Processing of IL-33 by neutrophil proteases, such as neutrophil elastase or cathepsin G, can also occur during bacterial, fungal, or viral infections. 48 In addition, mast cell tryptase and chymase were shown to generate the shorter mature forms of IL-33. 47 Although the numbers of attracted neutrophils and mast cells are negligibly small in our model (see Fig E5, A, in this article's Online repository at www.jacionline.org), they could be a potent source of IL-33-activating proteases, although SplD does not cause direct mast cell degranulation (see Fig E5, B) . However, thus far, the mechanism of IL-33 cleavage in SplDtreated mice remains a matter of speculation.
To block the IL-33 pathway, we treated mice with intratracheal applications of sST2. In contrast to former studies involving sST2, we applied sST2 intratracheally to mimic the noninvasive administration route of therapeutic inhalers. sST2 treatment during SplD sensitization resulted in diminished eosinophilic attraction to the airways, lower IL-33 and eotaxin levels, lower numbers of IL-13
1 ILC2s and CD4 1 T cells in BALF, and less IL-5 and IL-13 production in local draining lymph nodes. In contrast, intratracheal application of sST2 did not reduce SplD-specific IgE levels. This is possibly due to the intratracheal administration route because the IL-33 pathway was shown to interfere with IgE production in ST2 2/2 mice by using HDM 49 or a mix of allergens from A alternata, Aspergillus species, or HDM. 50, 51 In a study by Willart et al, 25 mice injected intraperitoneally with sST2 had reduced levels of HDM-specific IgE, whereas no effect on T H 2 cytokine levels in the lymph nodes could be seen. SplDinduced airway resistance was nonsignificantly decreased, and airway remodeling was unaffected by sST2 treatment.
DCs are known to be the primary sensors of antigens and infectious agents in the airways, and they initiate appropriate adaptive immune responses. 52 During allergic sensitization, IL-33 can activate DC maturation, resulting in expression of costimulatory molecules, priming of T cells, and ultimately production of T H 2 cytokines.
53,54 IL-33 treatment was shown to increase DC numbers in the lungs, whereas local T-and B-cell populations were not affected. 54 We have demonstrated that SplD treatment attracts DCs to the lung, as well as the local lymph nodes, where they probably prime naive T cells for differentiation into T H 2 cells. We observe that SplD induced migration of DCs to the local lymph nodes. As expected, DC activation was IL-33 dependent because it was reduced in mice treated with sST2.
These results prompted us to analyze the role of the adaptive immune system in our experimental model of SpD-induced asthma by using Rag2 2/2 mice. Importantly, eosinophilia, SplD-specific IgE production and goblet cell hyperplasia were completely abolished in Rag2 2/2 mice that received SplD. This demonstrates an essential function of the adaptive immune system in SplD-induced allergic airway inflammation. Because IL-33 levels were unaltered in SplD-treated Rag2 2/2 mice, IL-33 must act upstream of T-cell sensitization, probably by tuning DCs. Moreover, data clearly show that the pronounced eosinophilia in the inflamed airways and lungs was not elicited by IL-33 directly but mediated by adaptive immune cells. In agreement with this, Rag2 2/2 mice treated with HDM had very few eosinophils in the airways and reduced goblet cell metaplasia. 33 At first glance, our findings appear to contradict reports by Halim et al, 55, 56 who showed that ILC2s rather than T cells are important at the initiation stage of papain-induced allergic inflammation (days 2-3), promoting type 2 cytokine production, eosinophilia, and mucus hyperproduction. However, at later stages (days 14-21), CD4
1 T cells were the main producers of T H 2 cytokines. 57 After 2 weeks of SplD treatment, we found, in addition to infiltration of CD4 1 T cells, a significant expansion of ILC2s in the airways of SplD-treated wild-type mice. It appears plausible that also in our model the initial response to SplD is carried out mainly by resident ILC2s. However, the lack of inflammation in Rag2 2/2 mice after 2 weeks of SplD exposure shows that an amplification of this initial ILC2-mediated response by T cells is required for development of the observed eosinophilic type 2 airway inflammation in wild-type mice.
We have previously shown that Staphylococcus aureus enterotoxin B, a potent T cell-activating agent, can break immune tolerance in the airways. In the presence of this toxin, intratracheal application of OVA, an otherwise inert protein, primes a T H 2 response characterized by bronchial hyperreactivity and the production of specific IgE. 58 This is regulated by activation of inflammatory DCs and polyclonal T cells independent of the IL-1 receptor pathway. 59 Similarly, SplD promoted production of OVA-specific IgE antibodies when given in combination with OVA. Importantly, in our experimental model intratracheal application of OVA alone did not elicit OVA-specific IgE production, which indicates that it functions as a model of airway tolerance. Prior priming by systemic application of OVA together with an adjuvant is usually required to render OVA allergenic. 60 Hence our data indicate that SplD is capable of breaking tolerance in the airways.
Next to SplD, we showed that SplF can also induce an eosinophilic inflammatory response and allergic sensitization in mice. SplF shares 94.6% sequence homology with SplD. 61 Considering its high prevalence of 71% 62 in S aureus strains, our findings make SplF another relevant S aureus-derived allergen.
Our observations support the hypothesis that S aureus is persistently colonizing the nasal mucosa of patients protected by a biofilm or inside of immune cells 4 and constantly producing a panel of factors that could initiate and/or aggravate a T H 2-biased immune response. Chronic exposure to S aureus-secreted proteins, such as Spls, would also hinder resolution of the inflammation, fostering chronification.
In summary, we have demonstrated that SplD causes a T H 2 response in an IL-33-dependent manner because T H 2 cytokine production and eosinophilic airway inflammation could be controlled by sST2 treatment. This identifies IL-33 as a potential therapeutic target in patients with chronic rhinosinusitis and asthma who are carriers of S aureus.
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Key messages
d Sensitization with SplD causes T H 2-biased allergic airway inflammation in mice accompanied by release of the innate cytokine IL-33.
METHODS
Recombinant protein production
Recombinant SplD and SplF were produced in the Bacillus subtilis strain 6051HGW LS8P-D, which lack the proprietary proteases WprA, Epr, Bpr, NprB, NprE, Vpr, Mpr, and AprE, as described in detail previously.
E1 Cellfree supernatants were collected and subjected to tangential flow filtration to exchange the buffer with 20 mmol/L Tris/HCl (pH 7.5). SplD was purified by means of ion-exchange chromatography on an SP Sepharose Fast Flow column (GE Healthcare, Fairfield, Conn), followed by a 2-step purification with centrifugal filter units (Amicon Ultra 30K/10K; Merck Millipore, Billerica, Mass). Thereby the buffer was exchanged with PBS. The quality of the native SplD preparation was verified by using SDS-PAGE. Recombinant murine sST2 was generated and purified with standard chromatographic procedures from sST2-His transfected HEK-293 cells at the VIB Protein Service Facility, VIB Center for Inflammation Research (Ghent, Belgium).
Organ processing
Blood was collected in EDTA Microvettes 200Z (Sarstedt, N€ umbrecht, Germany) and centrifuged for 10 minutes at 3000 rpm, and serum was collected and stored at 2208C before further analysis. BALF was collected by rinsing the airways 3 times with 0.3 mL of 5% BSA (Sigma-Aldrich, Diegem, Belgium) in PBS with complete protease inhibitor cocktail (Roche Diagnostics, Anderlecht, Belgium) and 2 times with 1 mL of 0.2% ETDA (Sigma-Aldrich) in PBS and kept at 48C. Red blood cells were lysed for 2 minutes with VersaLyse buffer (Beckman Coulter, Suarl ee, Belgium). Cells were used for fluorescence-activated cell sorting (FACS) analysis. Lungs were perfused with 10 mL of 0.9% NaCl (Braun, Meslungen, Germany). The left lobe of the lung was fixed with 10% formalin (Sigma-Aldrich) for paraffin embedding, whereas the right lobes were either snap-frozen or minced and digested with 1% collagenase type II (Worthington Biochemical) for FACS analysis. Snap-frozen lungs were homogenized for 2 minutes at 50 oscillations per second with 10 times more wt/vol T-Per Tissue Protein Extraction reagent (Thermo Fisher Scientific, Waltham, Mass) with 13 HALT protease inhibitor cocktail kit (Thermo Fisher Scientific) by using the TissueLyser LT (Qiagen, Antwerp, Belgium). After 10 minutes of centrifugation at 3000 rpm, supernatants were collected and repeatedly centrifuged at 15,000 rpm for 3 minutes. Supernatants were collected as lung homogenates, and protein concentrations were measured with the Bio-Rad Protein assay (Bio-Rad, Temse, Belgium).
AECII sorting and in vitro stimulation with SplD
AECIIs were sorted from 3 naive C57BL/6J WT mice, as previously described. After sorting, cells were stimulated for 0, 1, and 5 hours with 25 mg/ mL SplD in serum free IMDM medium (Gibco) and lysed with T-Per buffer (Thermo Fisher Scientific) containing 13 HALT protease inhibitor cocktail kit (Thermo Fisher Scientific). Protein concentrations were measured by using the Bio-Rad Protein assay (Bio-Rad).
Lymph node restimulation assay
Peribronchial lymph nodes were collected and put through a 70-mm mesh. Red blood cells were lysed with VersaLyse buffer (Beckman Coulter), and lymph node cells were seeded in triplicates per condition at 2 3 10 5 cells/well in RPMI medium (Gibco) with 10% FBS (Gibco) and Pen/Strep (Gibco) in a 96-well plate. The wells were either uncoated or coated with 2 mg/mL purified anti-mouse CD3 (eBioscience, San Diego, Calif) for 2 hours before cell incubation. Purified anti-mouse CD28 (eBioscience) was added to the CD3-stimulated cells to reach a final concentration of 2 mg/mL, and unstimulated controls were filled with RPMI medium to a final volume of 200 mL/well. Cells were incubated for 5 days at 378C in a 5% CO 2 atmosphere, and supernatants were used for IL-5 and IL-13 analysis.
Western blotting
Twenty-five micrograms of protein of lung homogenates or lysed AECIIs per slot were loaded on a 15% Tris/HCl gel, separated by means of SDS-PAGE, and transferred to a nitrocellulose membrane (Bio-Rad). For Western blotting, mouse IL-33 antigen affinity-purified polyclonal goat IgG (dilution 1:300; R&D Systems) antibody and donkey anti-goat horseradish peroxidase (HRP; dilution 1:5,000; Santa Cruz Biotechnology, Heidelberg, Germany) and rabbit anti-glyceraldehyde-3-phosphate dehydrogenase antibody (dilution 1:10,000; Sigma-Aldrich) in combination with the donkey anti-rabbit HRP antibody (dilution 1:2,000; GE Healthcare) were used. For pMLKL and mixed lineage kinase domain-like protein (MLKL) Western blots, lungs were homogenized with the addition of PhosStop (Roche Diagnostics) in the above mentioned lysis buffer. A cell lysate of necrotic TNF-a-treated CT26 cells was used as a positive control. Anti-MLKL (phosphoS358, dilution 1:2,000; Abcam, Cambridge, United Kingdom) in combination with the donkey anti-rabbit HRP antibody (dilution 1:2,000; GE Healthcare) and anti-MLKL clone 3H1 (dilution 1:1,000; Merck Millipore) in combination with the anti-rat IgG HRP-linked antibody (dilution 1:2,000; Cell Signaling Technology, Leiden, The Netherlands) were used. Bands were visualized with the Immobilon Western Chemiluminescence HRP substrate (Merck Millipore). Four mice were tested per group for lung homogenates and 3 for AECIIs; one representative series is shown. Semiquantitative analysis of band intensities was performed by measuring the area under the peak of plotted lanes with ImageJ software (National Institutes of Health, Bethesda, Md).
Immunofluorescence staining
Formalin-fixed and paraffin-embedded lung tissues were cut into 5-mm sections. Sections were deparaffinized, and nonspecific binding sites were blocked with 3% normal horse serum (Vector Laboratories, Peterborough, United Kingdom) in PBS. Sections were incubated overnight at 48C with the following primary antibodies: mouse IL-33 (dilution 1:50; R&D Systems) in combination with anti-proSPC antibody (1:1000; Merck Millipore). As secondary antibodies, donkey anti-goat Alexa Fluor 488 (1:750) antibody (Invitrogen, Thermo Fisher Scientific) was used in combination with donkey anti-rabbit Alexa Fluor 594 (1:750; Invitrogen). Slides were mounted with Vectashield Mounting medium for fluorescence with 49-6-diamidino-2-phenylindole dihydrochloride (Vector Laboratories). Images were obtained with a Zeiss Axioplan 2 confocal microscope (Zeiss, Oberkochen, Germany).
Immunohistochemistry
Formalin-fixed and paraffin-embedded lung tissues were cut into 5-mm sections. Sections were deparaffinized and rehydrated, and antigen retrieval with citrate buffer (2 mmol/L citric acid and 10 mmol/L sodium citrate, Sigma-Aldrich), peroxidase blockage with 3% H 2 O 2 (Sigma-Aldrich), and blockage of nonspecific binding sites with 3% goat serum (Sigma-Aldrich) in PBS with 0.4% Triton-X 100 (Sigma-Aldrich) were performed. Slides were stained with either anti-PAR2 antibody (dilution 1:100; Abcam) in combination with goat anti-rabbit HRP (1:100), with anti-smooth muscle actin (1:3000 dilution; Abcam) in combination with goat anti-rabbit HRP (1:200), or with purified rat anti-mouse CD45 (dilution 1:100; BD Biosciences, San Jose, Calif) in combination with biotin goat anti-rat immunoglobulin (dilution 1:500; BD Bioscience). The CD45 staining signal was amplified by using the Vectastain elite ABC kit (Vector Laboratories). All sections were developed with the DAB1 Substrate chromogen system (Dako, Glostrup, Denmark) and counterstained with hematoxylin (Sigma-Aldrich), dehydrated, and mounted with Pertex (Histolab, Gothenburg, Sweden). Images were taken with an AxioScanZ.1 (Zeiss, Germany) by using a 203 Plan-Apochromat 0.8 NA dry objective captured with a Hitachi HV-F202SCL camera. Percentages of CD45 1 and PAR2 1 area of lung sections were quantified by using the trainable WEKA segmentation tool of the Fiji software. Airway smooth muscle thickness was calculated as the radius of the positively smooth muscle actin-stained peribronchial smooth muscle area.
Toluidine blue staining
Lung sections were deparaffinized, rehydrated, and stained for 15 minutes with 0.1% Toluidine blue (Sigma-Aldrich) in 7% ethanol and 1% NaCl, pH 2.3, followed by dehydration with 100% ethanol and mounting with Pertex (Histolab). Mast cell numbers were quantified in 5 nonadjacent lung sections per mouse (n 5 7). Images were acquired with an AxioScanZ.1 (Zeiss) with a 203 Plan-Apochromat 0.8 NA dry objective captured with a Hitachi HV-F202SCL camera.
Periodic acid-Schiff staining
Deparaffinized and rehydrated lung sections were stained for mucusproducing goblet cells by using the periodic acid-Schiff kit (Sigma-Aldrich). The magenta stained goblet cells were counted in airways with a perimeter of 800 to 2000 mm by using Aviso software (Hillsboro, Ore).
TUNEL staining
Deparaffinized and rehydrated lung sections were stained with the TUNEL Apoptosis Detection Kit (Merck Millipore), according to the manufacturer's manual. As a positive control, 200 mg/mL DNAse I (Qiagen, Hilden, Germany) in 1 mg/mL BSA and Tris/HCl (pH 7.5) was applied for 10 minutes after the endogenous peroxidase-quenching step.
SplD-, SplF-, and OVA-specific IgE analysis Sera of mice were taken 48 hours after the last SplD application, and titers of SplD-specific IgE were performed by using an ELISA, as described previously.
E1 For OVA-or SplF-specific IgE measurements, 5 mg/mL OVA or SplF was used to coat the plates; otherwise, the assay was performed in the same way as for SplD-specific IgE.
HEK-Blue hTLR2 cell stimulation assay HEK-Blue hTLR2 (InvivoGen, San Diego, Calif) are TLR2 reporter cells that produce secreted embryonic alkaline phosphatase on TLR2 activation through NF-kB. HEK-Blue hTLR2 cells were stimulated with 50, 25, or 5 mg/ mL SplD at 378C in a 5% CO 2 atmosphere overnight. As a positive control, peptidoglycan was added at 1 mg/mL. Cell supernatants were diluted 1 in 10 with QUANTI-Blue (InvivoGen), according to the supplier's manual, and the secreted embryonic alkaline phosphatase activity was measured at 620 nm after 24 hours. Untreated cell supernatants were used as a negative control. All conditions were measured in duplicates, and the experiment was repeated 3 times.
Generation of PAR2 reporter HEK 293 T cells
Cells were seeded 1 day before transfection at a density of 4 3 10 4 cells/ well in 1 mL of Dulbecco modified Eagle medium (DMEM) and 10% FCS medium in 24 well-plates. Cells were transfected by means of calcium-phosphate precipitation with an NF-kB-inducible luciferase reporter plasmid, a b-galactosidase reporter for normalization of the luciferase values, and a human PAR2 expression vector. For control transfections without PAR2, the total amount of DNA was equalized with empty vector DNA. After 4 hours of incubation at 378C in a 5% CO 2 atmosphere, the medium was replaced with fresh DMEM with 10% FCS. Twenty-four hours after transfection, cells were used for the PAR2 activation assay. (Fig E2, B) and flow cytometric analysis of eosinophils (Fig E2, C) , neutrophils (Fig E2, D) , and CD4
1 T cells (Fig E2, E) in BALF and eosinophils in lungs (Fig E2, F) . G, IL-33 measurement in lung homogenates by using Luminex. H, SplD-specific IgE levels in serum measured by means of ELISA of SplD-treated (Fig E3, A) , eosinophil (Fig E3, B) , neutrophil ( Fig  E3, C) , and CD4 1 T-cell (Fig E3, D) Fig E3, F) counts in the lungs, measured by means of flow cytometry. G and H, IL-33 (Fig E3, G) and eotaxin (Fig E3, H) levels measured in lung homogenates by using Luminex. I, SplF-specific IgE levels in sera of PBS-or SplF-treated mice. J, Representative images of anti-CD45, periodic acid-Schiff (PAS), anti-smooth muscle actin (SMA), and anti-PAR2 stainings of lung sections of SplF-treated mice.
FIG E4.
Representative dot plots and gating strategy of ILCs positive for intracellular IL-5 or IL-13 in BALF of wild-type C57BL/6 J mice repeatedly exposed to 45 
